Conference abstract · 3 Dec 2018
Conference abstractPublished 27 Dec 2018
The 14F7 Monoclonal Antibody: Past, present, and future for theragnosis in cancer
Center for Molecular Immunology, Cuba
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The relevance of certain gangliosides in tumor growth and metastatic dissemination has been well documented. GM3 (NeuGc) ganglioside is particularly interesting due to its restrictive expression in normal human and chicken tissues. On the other hand, previous studies have shown that 14F7 Mab (IgG1) is a very specific anti-NeuGcGM3 ganglioside inducing cell death accompanied by cellular swelling, membrane lesion formation, and cytoskeleton activation, suggesting an oncosis-like novel phenomenon. The fact that the 14F7 Mab is able to very specific recognize in vitro and in vivo by IHC and immune gammagraphy studies the P3X63 murine myeloma cell line, the spontaneous epithelial chicken ovarian cancer and the human breast cancer that over-express the GM3 (NeuGc) ganglioside makes this Mab an important tool with anti-proliferative anti-tumor effects in vitro and in vivo animal models. A dose-escalation Phase I clinical trial is ongoing in Cuba with the humanized 14F7 Mab for studying the pharmacokinetics, toxicity and any evidence of anti-tumor effect in solid tumors over-expressing the GM3 (NeuGc). These two properties, the very specificity for recognizing tumors that over-express this ganglioside and its capability to have anti-tumor effect make this Mab an ideal drug for personalized medicine and teragnosis of cancer patients over-expressing the GM3 (NeuGc) ganglioside.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 6 Jan 2021
New conjugated monoclonal antibodies: Area of a promising therapy in metastatic breast cancer.
Research article · 2017
Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Antiand#195;and#162;and#194;and#8364;and#194;and#8220;Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer
Research article · 2017
Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer
Conference abstract · 15 Apr 2014
Epitope profiling the plasma proteome via specific monoclonal antibody libraries results in high accuracy for the detection of lung, breast, colon and prostate cancers
More from this journal
The newest in Journal of Clinical & Experimental Pathology.
Research article · 24 Feb 2025
Combining Urinary Biomarker Panels and Machine Learning For Earlier Detection of Pancreatic Cancer
Research article · 3 Feb 2025
Outbreak of Crimean Congo Haemorrhagic Fever in Northern Senegal in 2022
Review article · 16 Jan 2025
Recent Updates on Huntington Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pathology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Angel Casaco”
